I

Intesmiran

Product

by Moderna

Heard in 2 episodes across 2 shows since Aug 2026

Intesmiran is referenced as Moderna’s individualized mRNA cancer-vaccine candidate, designed to be used with immune-checkpoint therapy for melanoma and potentially other cancers.

Episodes

2
across 2 shows

First heard

Aug 2026

Expert statements

2
2 positive

Episodes per month

Public PodLume episodes featuring it, over the last year.

Show the data
MonthEpisodes
Nov 20250
Dec 20250
Jan 20260
Feb 20260
Mar 20260
Apr 20260
May 20260
Jun 20260
Jul 20260
Aug 20261
Sep 20261
Oct 20260

What experts have said about Intesmiran

2 statements · 2 positive

  1. Bryce LeskePositiveAug 23, 2026· Equity Mates Investing Podcast

    Intismarin trains immune systems to target tumor mutations.

    “It's an experimental vaccine that trains the patient's immune system to fight tumors by targeting mutations in cancer cells.”

    Listen at 3:53

    Open the episode · Moderna’s skin cancer breakthrough, a cheap stock for the Community Portfolio & can you time your investments?
  2. Bryce LeskePositiveAug 23, 2026· Equity Mates Investing Podcast

    High-risk melanoma patients could benefit as early as next year if approved.

    “could start benefiting from this as early as next year if regulators approve it”

    Listen at 6:05

    Open the episode · Moderna’s skin cancer breakthrough, a cheap stock for the Community Portfolio & can you time your investments?
Filter the statements →

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

2 episodes featuring Intesmiran, newest first

Intesmiran · PodLume